(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests - 2Who was Haytham Ali Tabatabai, Hezbollah's military leader killed by Israel?
- 3Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say
- 4Muslim nations condemn new Israeli death penalty law
- 5A soft launch, an unfollow and a lot of questions: Breaking down the 'Summer House' romance blowing up group chats
- 2025 Was Another Exceptionally Hot Year
- 10 Asian Countries Perfect for Solo Female Travelers
- Washington resident is infected with a different type of bird flu
- Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
- Display of Netanyahu's severed head 'incites public to murder PM', Likud says in official complaint
- Tablets: Upgrade Your Understanding Experience
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- The Fate of Rest: Patterns in Shrewd Beds
- The Reduced Portage Horse: An Inheritance Reconsidered for Present day Experience
